BioAge’s Hopes For Combo Obesity Drug Dim Due To Liver Safety
Phase II Trial, Designed With Lilly, Cancelled
The company discontinued the Phase II STRIDES study testing azelaprag as monotherapy and in combination with Lilly’s tirzepatide in obesity.
The company discontinued the Phase II STRIDES study testing azelaprag as monotherapy and in combination with Lilly’s tirzepatide in obesity.